Pharming Group NV is projected to report Q2 2026 revenue of $82.50 million and an EPS of $0.20, with the current stock price of $1.25 sitting well below the average analyst price target of $2.15. The primary focus for investors this quarter is the commercial trajectory and patient enrollment rates for Joenja (leniolisib) following its expansion into international markets.
While Ruconest provides a stable cash flow base, the market is looking for Joenja to become the dominant growth engine. Analysts will specifically monitor management's guidance on the progress of the leniolisib clinical pipeline for broader primary immunodeficiency indications.